Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD8 expression
i
Other names:
CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
925
Related biomarkers:
Expression
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
CD8 expression
Prostate Cancer
CD8 expression
Prostate Cancer
atezolizumab + enzalutamide capsule
Sensitive: B - Late Trials
atezolizumab + enzalutamide capsule
Sensitive
:
B
atezolizumab + enzalutamide capsule
Sensitive: B - Late Trials
atezolizumab + enzalutamide capsule
Sensitive
:
B
CD8 expression
Melanoma
CD8 expression
Melanoma
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
CD8 expression
Urothelial Cancer
CD8 expression
Urothelial Cancer
PF-06801591
Sensitive: C3 – Early Trials
PF-06801591
Sensitive
:
C3
PF-06801591
Sensitive: C3 – Early Trials
PF-06801591
Sensitive
:
C3
CD8 expression
Melanoma
CD8 expression
Melanoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
CD8 expression
Melanoma
CD8 expression
Melanoma
ipilimumab
Sensitive: C3 – Early Trials
ipilimumab
Sensitive
:
C3
ipilimumab
Sensitive: C3 – Early Trials
ipilimumab
Sensitive
:
C3
CD8 expression
Renal Cell Carcinoma
CD8 expression
Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
CD8 expression
Solid Tumor
CD8 expression
Solid Tumor
TAB004
Sensitive: C3 – Early Trials
TAB004
Sensitive
:
C3
TAB004
Sensitive: C3 – Early Trials
TAB004
Sensitive
:
C3
CD8 expression
Esophageal Squamous Cell Carcinoma
CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login